Financial Data and Key Metrics Changes - Order bookings for Q3 were $821 million, up almost 12% sequentially, and revenues were $761 million, up almost 17% from Q3 last year, driven primarily by organic growth [10][11] - Adjusted earnings from operations in Q3 were $80 million, in line with expectations, with earnings per share at $0.48 on an adjusted basis [10][16] - The gross margin for Q3 was 29.6%, a 111 basis point decrease from last year, mainly due to program mix [16] Business Line Data and Key Metrics Changes - In life sciences, order backlog was $1.1 billion, with revenues for the quarter at $391 million, the second highest in ATS's history [11][12] - The food and beverage segment had a Q3 order backlog of CAD 203 million, while the energy segment's order backlog reached a record CAD 296 million, up 87% over Q3 last year [12] - Consumer products backlog reached a record CAD 321 million, supported by a large enterprise warehouse packaging automation program [13] Market Data and Key Metrics Changes - The company reported strong demand in life sciences, particularly in radiopharma and GLP-1 auto-injectors, with ongoing customer engagement [11][12] - The energy sector is seeing significant growth due to refurbishment and life extension projects for nuclear reactors, alongside new build programs [12][13] - The transportation segment continues to reflect smaller-scale opportunities, with a cautious approach to larger projects [67] Company Strategy and Development Direction - The company is focused on margin expansion, capital allocation, and leveraging its strong lean operating system to drive sustained results [4][7] - Recent leadership changes aim to strengthen accountability and improve customer alignment, particularly in the services business [6] - The company plans to deploy capital with a high level of discipline, emphasizing margin improvement and new technologies [29][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the depth and capability of the organization, highlighting a healthy and diversified order backlog [14][21] - The macro environment remains dynamic amid geopolitical and trade uncertainty, but the company has not been materially impacted by tariffs [19] - Management remains optimistic about the outlook for ATS, with a focus on core end markets and margin expansion potential [30] Other Important Information - The company incurred CAD 5.5 million in restructuring costs during the quarter, with total costs expected to be approximately CAD 20 million [18] - Cash flows from operating activities were CAD 115 million, with non-cash working capital as a percentage of revenues improving to 16.4% [20] Q&A Session Summary Question: Doug's priorities in the first 90 days - Doug emphasized focusing on core end markets, realizing margin expansion potential, and disciplined capital deployment [28] Question: Correlation between margin improvement and gross margin change - Management indicated that gross margin changes reflect program execution and backlog dynamics, with ongoing opportunities for improvement [31][35] Question: Insights on nuclear and life sciences segments - Management noted strong backlog in nuclear life extension projects and ongoing growth in life sciences, particularly in radiopharma [39][42] Question: Working capital targets and M&A plans - Doug mentioned that while it's premature to set new working capital targets, there is a focus on disciplined capital allocation, including M&A opportunities [45][46] Question: Updates on GLP-1 and other therapies - Management confirmed ongoing strong demand for GLP-1 therapies while also diversifying the pipeline with new applications in radiopharma and oncology [54][56] Question: Transportation segment outlook - The transportation segment is viewed cautiously, with a focus on targeted niches rather than large-scale projects [66] Question: Context on bookings growth - Management expressed confidence in a healthy pipeline and robust bookings outlook despite timing impacts [88]